TY  - GEN
AU  - Czuczman,M S
AU  - Leonard,J P
AU  - Jung,S
AU  - Johnson,J L
AU  - Hsi,E D
AU  - Byrd,J C
AU  - Cheson,B D
TI  - Phase II trial of galiximab (anti-CD80 monoclonal antibody) plus rituximab (CALGB 50402): Follicular Lymphoma International Prognostic Index (FLIPI) score is predictive of upfront immunotherapy responsiveness
SN  - 1569-8041
PY  - 2012///1226
KW  - Adult
KW  - Aged
KW  - Aged, 80 and over
KW  - Antibodies, Monoclonal
KW  - administration & dosage
KW  - Antibodies, Monoclonal, Murine-Derived
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - therapeutic use
KW  - Disease-Free Survival
KW  - Female
KW  - Humans
KW  - Immunization, Passive
KW  - Induction Chemotherapy
KW  - Kaplan-Meier Estimate
KW  - Lymphoma, Follicular
KW  - drug therapy
KW  - Male
KW  - Middle Aged
KW  - Rituximab
KW  - Severity of Illness Index
KW  - Treatment Outcome
KW  - Young Adult
N1  - Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1093/annonc/mdr620
ER  -